Obecure Initiates Phase II Weight Gain Prevention Study for Patients Taking Zyprexa

RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure has conducted the first initiation visit for its Phase II clinical trial to evaluate the efficacy of the company’s OBE101 drug candidate for prevention of weight gain in patients treated with Zyprexa, (olanzapine) an antipsychotic medication. The study is a double-blinded, placebo-controlled multicenter trial in about 78 subjects over a period of four months. The study, approved by Health Canada and the central IRB, will be conducted at several psychiatric medical centers across Canada and will start at Penticton, BC. The trial is being conducted with the partial financial support of Eli Lilly & Co., the manufacturer of Zyprexa.